Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?
Identifieur interne : 000994 ( PubMed/Checkpoint ); précédent : 000993; suivant : 000995Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?
Auteurs : J-M Senard [France] ; A. PathakSource :
- Revue neurologique [ 0035-3787 ] ; 2010.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiparkinson Agents.
- complications : Parkinson Disease.
- drug therapy : Multiple System Atrophy, Shy-Drager Syndrome.
- etiology : Multiple System Atrophy, Shy-Drager Syndrome.
- Diagnosis, Differential, Humans.
Abstract
The aim of this short review is to illustrate, using orthostatic hypotension as an example, the clinical problems related to autonomic features in Parkinson's disease. Orthostatic hypotension is frequently encountered in Parkinson's disease and its diagnosis remains manometric (a fall of at least 20 and/or 10 mmHg in standing blood pressure). It is often associated with supine hypertension to be taken into account before prescribing. To distinguish between the role of disease and of drugs (not only antiparkinsonian drugs), a simple clinical test of autonomic nervous system activity (deep breathing test and standing test with measurement of 30/15 ratio) can be used. When diagnosis with multisystem atrophy is discussed, cardiac [¹²³I]-metaiodobenzylguanidine (MIBG) scintigraphy is of value showing in Parkinson's disease a decreased uptake of the radiopharmaceutical indicating postganglionic sympathetic denervation. Concerning treatment, nonpharmacological methods have to be systematically used since no drug has been specifically evaluated for the treatment of orthostatic hypotension of Parkinson's disease.
DOI: 10.1016/j.neurol.2010.07.007
PubMed: 20817229
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:20817229Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?</title><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J-M" last="Senard">J-M Senard</name><affiliation wicri:level="3"><nlm:affiliation>Inserm U858, Service de Pharmacologie Clinique, Université de Toulouse, CHU de Toulouse, 37 Allées-Jules-Guesde, 31000 Toulouse, France. senard@cict.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm U858, Service de Pharmacologie Clinique, Université de Toulouse, CHU de Toulouse, 37 Allées-Jules-Guesde, 31000 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Pathak, A" sort="Pathak, A" uniqKey="Pathak A" first="A" last="Pathak">A. Pathak</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20817229</idno><idno type="pmid">20817229</idno><idno type="doi">10.1016/j.neurol.2010.07.007</idno><idno type="wicri:Area/PubMed/Corpus">000A47</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A47</idno><idno type="wicri:Area/PubMed/Curation">000A07</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A07</idno><idno type="wicri:Area/PubMed/Checkpoint">000A07</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A07</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?</title><author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J-M" last="Senard">J-M Senard</name><affiliation wicri:level="3"><nlm:affiliation>Inserm U858, Service de Pharmacologie Clinique, Université de Toulouse, CHU de Toulouse, 37 Allées-Jules-Guesde, 31000 Toulouse, France. senard@cict.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Inserm U858, Service de Pharmacologie Clinique, Université de Toulouse, CHU de Toulouse, 37 Allées-Jules-Guesde, 31000 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Pathak, A" sort="Pathak, A" uniqKey="Pathak A" first="A" last="Pathak">A. Pathak</name></author></analytic><series><title level="j">Revue neurologique</title><idno type="ISSN">0035-3787</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term><term>Diagnosis, Differential</term><term>Humans</term><term>Multiple System Atrophy (drug therapy)</term><term>Multiple System Atrophy (etiology)</term><term>Parkinson Disease (complications)</term><term>Shy-Drager Syndrome (drug therapy)</term><term>Shy-Drager Syndrome (etiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple System Atrophy</term><term>Shy-Drager Syndrome</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Multiple System Atrophy</term><term>Shy-Drager Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Diagnosis, Differential</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this short review is to illustrate, using orthostatic hypotension as an example, the clinical problems related to autonomic features in Parkinson's disease. Orthostatic hypotension is frequently encountered in Parkinson's disease and its diagnosis remains manometric (a fall of at least 20 and/or 10 mmHg in standing blood pressure). It is often associated with supine hypertension to be taken into account before prescribing. To distinguish between the role of disease and of drugs (not only antiparkinsonian drugs), a simple clinical test of autonomic nervous system activity (deep breathing test and standing test with measurement of 30/15 ratio) can be used. When diagnosis with multisystem atrophy is discussed, cardiac [¹²³I]-metaiodobenzylguanidine (MIBG) scintigraphy is of value showing in Parkinson's disease a decreased uptake of the radiopharmaceutical indicating postganglionic sympathetic denervation. Concerning treatment, nonpharmacological methods have to be systematically used since no drug has been specifically evaluated for the treatment of orthostatic hypotension of Parkinson's disease.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20817229</PMID><DateCreated><Year>2010</Year><Month>09</Month><Day>27</Day></DateCreated><DateCompleted><Year>2010</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2010</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Print"><Volume>166</Volume><Issue>10</Issue><PubDate><Year>2010</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation></Journal><ArticleTitle>Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?</ArticleTitle><Pagination><MedlinePgn>779-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurol.2010.07.007</ELocationID><Abstract><AbstractText>The aim of this short review is to illustrate, using orthostatic hypotension as an example, the clinical problems related to autonomic features in Parkinson's disease. Orthostatic hypotension is frequently encountered in Parkinson's disease and its diagnosis remains manometric (a fall of at least 20 and/or 10 mmHg in standing blood pressure). It is often associated with supine hypertension to be taken into account before prescribing. To distinguish between the role of disease and of drugs (not only antiparkinsonian drugs), a simple clinical test of autonomic nervous system activity (deep breathing test and standing test with measurement of 30/15 ratio) can be used. When diagnosis with multisystem atrophy is discussed, cardiac [¹²³I]-metaiodobenzylguanidine (MIBG) scintigraphy is of value showing in Parkinson's disease a decreased uptake of the radiopharmaceutical indicating postganglionic sympathetic denervation. Concerning treatment, nonpharmacological methods have to be systematically used since no drug has been specifically evaluated for the treatment of orthostatic hypotension of Parkinson's disease.</AbstractText><CopyrightInformation>Copyright © 2010 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Senard</LastName><ForeName>J-M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Inserm U858, Service de Pharmacologie Clinique, Université de Toulouse, CHU de Toulouse, 37 Allées-Jules-Guesde, 31000 Toulouse, France. senard@cict.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathak</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="N">Multiple System Atrophy</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012791" MajorTopicYN="N">Shy-Drager Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>06</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20817229</ArticleId><ArticleId IdType="pii">S0035-3787(10)00333-4</ArticleId><ArticleId IdType="doi">10.1016/j.neurol.2010.07.007</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Toulouse</li></settlement></list><tree><noCountry><name sortKey="Pathak, A" sort="Pathak, A" uniqKey="Pathak A" first="A" last="Pathak">A. Pathak</name></noCountry><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J-M" last="Senard">J-M Senard</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000994 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000994 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:20817229
|texte= Neurogenic orthostatic hypotension of Parkinson's disease: what exploration for what treatment?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:20817229" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |